LPL Financial’s Alexion Pharmaceuticals ALXN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-11,619
Closed -$2.13M 4493
2021
Q2
$2.13M Sell
11,619
-8,415
-42% -$1.44M ﹤0.01% 1924
2021
Q1
$3.06M Sell
20,034
-50,890
-72% -$7.87M ﹤0.01% 1559
2020
Q4
$11.1M Buy
70,924
+7,628
+12% +$980K 0.01% 705
2020
Q3
$7.24M Sell
63,296
-494
-0.8% -$53.3K 0.01% 775
2020
Q2
$7.16M Buy
63,790
+15,892
+33% +$1.69M 0.01% 708
2020
Q1
$4.3M Buy
47,898
+1,669
+4% +$164K 0.01% 807
2019
Q4
$5M Buy
46,229
+7,837
+20% +$838K 0.01% 837
2019
Q3
$3.76M Sell
38,392
-757
-2% -$85.3K 0.01% 920
2019
Q2
$5.13M Buy
39,149
+1,374
+4% +$177K 0.01% 782
2019
Q1
$5.11M Buy
37,775
+7,759
+26% +$965K 0.01% 752
2018
Q4
$2.92M Buy
30,016
+824
+3% +$97.4K 0.01% 909
2018
Q3
$4.06M Buy
29,192
+1,026
+4% +$129K 0.01% 834
2018
Q2
$3.5M Buy
28,166
+457
+2% +$53.4K 0.01% 871
2018
Q1
$3.09M Buy
27,709
+5,260
+23% +$629K 0.01% 900
2017
Q4
$2.69M Sell
22,449
-2,804
-11% -$341K 0.01% 896
2017
Q3
$3.53M Buy
25,253
+9,927
+65% +$1.35M 0.01% 730
2017
Q2
$1.86M Sell
15,326
-11,223
-42% -$1.31M 0.01% 986
2017
Q1
$3.17M Buy
26,549
+3,316
+14% +$428K 0.02% 609
2016
Q4
$2.85M Sell
23,233
-1,323
-5% -$162K 0.02% 630
2016
Q3
$3.03M Buy
24,556
+10,540
+75% +$1.36M 0.03% 566
2016
Q2
$1.7M Buy
14,016
+5,380
+62% +$763K 0.01% 849
2016
Q1
$1.28M Sell
8,636
-1,242
-13% -$182K ﹤0.01% 1490
2015
Q4
$1.83M Sell
9,878
-1,506
-13% -$263K 0.01% 1235
2015
Q3
$1.86M Buy
11,384
+1,501
+15% +$274K 0.01% 871
2015
Q2
$1.84M Buy
9,883
+246
+3% +$42.5K 0.01% 954
2015
Q1
$1.63M Sell
9,637
-6,055
-39% -$1.1M 0.01% 1022
2014
Q4
$2.9M Buy
15,692
+524
+3% +$97.1K 0.02% 711
2014
Q3
$2.54M Buy
15,168
+3,407
+29% +$560K 0.02% 743
2014
Q2
$1.84M Buy
11,761
+1,142
+11% +$180K 0.01% 933
2014
Q1
$1.61M Sell
10,619
-2,514
-19% -$400K 0.01% 949
2013
Q4
$1.75M Buy
13,133
+3,041
+30% +$365K 0.01% 907
2013
Q3
$1.08M Sell
10,092
-438
-4% -$48.1K 0.01% 1144
2013
Q2
$971K Buy
+10,530
New +$1.01M 0.01% 1141

Other funds holding ALXN